Disease control with a second epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) after failure of a first TKI in Asian patients with non-small cell lung cancer (NSCLC)

18104 Background: Asian NSCLC patients are known to have higher response ratesto the EGFR TKI gefitinib(G) and erlotinib(E). Anecdotal reportssuggest some activity for a second EGFR TKI after f...